Overview
- Novo Nordisk, which announced the partnership Tuesday, will run pilots in R&D, manufacturing, and commercial teams with full rollout targeted by the end of 2026.
- The deal applies OpenAI’s models to sift large datasets, spot promising drug candidates, and cut the time it takes for treatments to reach patients.
- OpenAI will train Novo’s global staff to raise AI skills, with CEO Mike Doustdar saying the tools will boost scientists rather than replace them.
- Novo says the program is built with strict data protection, governance rules, and human oversight to keep use ethical and compliant.
- The move extends Novo’s broader AI strategy with partners like AWS, Microsoft, Google, Hugging Face, and Nvidia as it counters Eli Lilly’s recent gains in weight‑loss drugs.